Global Antibiotic R&D Partnership (GARDP)
Pierre Daram is an experienced professional in the pharmaceutical and biotechnology sectors, currently serving as an R&D Drug/Treatment Project Leader at the Global Antibiotic R&D Partnership (GARDP) since April 2022. Prior to this role, Pierre Daram held various leadership positions at Debiopharm International SA from August 2008 to April 2022, including Global Project Leader and Associate Director of Portfolio Management, where responsibilities encompassed strategic portfolio planning, risk assessment implementation, and communication with top management. Pierre Daram's experience also includes project management for late-stage oncology and infectious disease products, as well as scouting for in-licensing opportunities. Educational qualifications include an MBA in Biotech & Pharma Management from Universität für Weiterbildung Krems and a PhD in Molecular Biology from L'Institut Agro Montpellier.
This person is not in any offices
Global Antibiotic R&D Partnership (GARDP)
The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit organization that develops new antibiotic treatments for drug-resistant bacterial infections that pose the greatest threat to human health, and makes them accessible to the people who need them. It puts public health needs at the centre of antibiotic drug development to address both the immediate antimicrobial resistance (AMR) crisis and to ensure people continue to get access to essential antibiotics for generations to come. GARDP works through a global network including Brazil, India, Japan, and South Africa for antibiotic development and access. Its work is made possible by essential funding from donors and collaboration with over 100 R&D and access partners in over 20 countries. GARDP was created by the World Health Organization and the Drugs for Neglected Diseases initiative (DNDi) in 2016 and legally registered as the GARDP Foundation in Geneva, Switzerland in 2018. www.gardp.org